Trials / Completed
CompletedNCT00719745
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing primary liver transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf | oral |
| DRUG | MR4 | oral |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2008-07-22
- Last updated
- 2008-07-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00719745. Inclusion in this directory is not an endorsement.